Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus

Immunotherapy

Volumn 3, Issue 2, 2011, Pages 269-285

  Beasley, David Wc ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

monoclonal antibodies; passive immunization; vaccine; West Nile virus

Indexed keywords

CHIMERIC VACCINE; CHIMERIVAX; IMMUNOGLOBULIN; LIVE VACCINE; MONOCLONAL ANTIBODY; PREVENILE; RECOMBITEK; REPLIVAX; UNCLASSIFIED DRUG; VECTORED VIRUS VACCINE; VIRUS VACCINE; WEST NILE VACCINE; WN INNOVATOR;

EPIDEMIC; EUROPE; FLAVIVIRUS INFECTION; GENETIC ANALYSIS; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; INNATE IMMUNITY; MIDDLE EAST; NONHUMAN; NORTH AMERICA; PATHOGENESIS; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; UNITED STATES; VIRUS STRAIN; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

ANIMAL DISEASES; ANIMALS; EPIDEMICS; HUMANS; IMMUNOTHERAPY; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 79951766069     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.93     Document Type: Review

References (187)

1. Lindsey NP, Staples JE, Lehman JA, Fischer M: Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill. Summ. 59(2), 1-17 (2010).
2. Chowers MY, Green MS, Bin H et al.: Postepidemic serosurvey of West Nile fever in Israel. Eur. J. Clin. Microbiol. Infect. Dis. 24(12), 851-853 (2005). (Pubitemid 43042795)
3. Mostashari F, Bunning ML, Kitsutani PT et al.: Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358(9278), 261-264 (2001). (Pubitemid 32738963)
4. Zohrabian A, Hayes EB, Petersen LR: Cost-effectiveness of West Nile virus vaccination. Emerg. Infect. Dis. 12(3), 375-380 (2006).
5. Martina BE, Koraka P, Osterhaus AD: West Nile virus: is a vaccine needed? Curr. Opin. Investig. Drugs 11(2), 139-146 (2010).
6. Petersen LR, Roehrig JT: Flavivirus DNA vaccines - good science, uncertain future. J. Infect. Dis. 196(12), 1721-1723 (2007). (Pubitemid 351411928)
7. Diamond MS: Progress on the development of therapeutics against West Nile virus. Antiviral Res. 83(3), 214-227 (2009).
8. Widman DG, Frolov I, Mason PW: Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv. Virus Res. 72, 77-126 (2008).
9. Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J: Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development. Expert Rev. Vaccines 6(2), 183-191 (2007). (Pubitemid 46607454)
10. Dauphin G, Zientara S: West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25(30), 5563-5576 (2007). (Pubitemid 47031364)
11. Sampath A, Padmanabhan R: Molecular targets for flavivirus drug discovery. Antiviral Res. 81(1), 6-15 (2009).
12. Diamond MS: Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 5(6), E1000452 (2009).
13. Diamond MS, Mehlhop E, Oliphant T, Samuel MA: The host immunologic response to West Nile encephalitis virus. Front. Biosci. 14, 3024-3034 (2009).
14. Klein RS, Diamond MS: Immunological headgear: antiviral immune responses protect against neuroinvasive West Nile virus. Trends Mol. Med. 14(7), 286-294 (2008).
15. Davis LE, DeBiasi R, Goade DE et al.: West Nile virus neuroinvasive disease. Ann. Neurol. 60(3), 286-300 (2006). (Pubitemid 44520233)
16. Gyure KA: West Nile virus infections. J. Neuropathol. Exp. Neurol. 68(10), 1053-1060 (2009).
17. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ: Structure of West Nile virus. Science 302(5643), 248 (2003). (Pubitemid 37248748)
18. Brinton MA: The molecular biology of West Nile virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 56, 371-402 (2002).
19. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR: West Nile virus NS2B/NS3 protease as an antiviral target. Curr. Med. Chem. 15(27), 2771-2784 (2008).
20. Edgil D, Harris E: End-to-end communication in the modulation of translation by mammalian RNA viruses. Virus Res. 119(1), 43-51 (2006). (Pubitemid 43765978)
21. Lanciotti RS, Ebel GD, Deubel V et al.: Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298(1), 96-105 (2002). (Pubitemid 34734883)
22. Lanciotti RS, Roehrig JT, Deubel V et al.: Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286(5448), 2333-2337 (1999). (Pubitemid 30016893)
23. Jia XY, Briese T, Jordan I et al.: Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 354(9194), 1971-1972 (1999).
24. Bakonyi T, Ivanics E, Erdelyi K et al.: Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg. Infect. Dis. 12(4), 618-623 (2006).
25. Erdelyi K, Ursu K, Ferenczi E et al.: Clinical and pathologic features of lineage 2 West Nile virus infections in birds of prey in Hungary. Vector Borne Zoonotic Dis. 7(2), 181-188 (2007). (Pubitemid 47205934)
26. Outbreak of West Nile virus infection in Greece, July-August 2010. ECDC Threat Assessment, European Centre for Disease Prevention and Control, Sweden (2010).
27. Venter M, Human S, Zaayman D et al.: Lineage 2 West Nile virus as cause of fatal neurologic disease in horses, South Africa. Emerg. Infect. Dis. 15(6), 877-884 (2009).
28. Venter M, Steyl J, Human S et al.: Transmission of West Nile virus during horse autopsy. Emerg. Infect. Dis. 16(3), 573-575 (2010).
29. Venter M, Swanepoel R: West Nile virus lineage 2 as a cause of zoonotic neurological disease in humans and horses in southern Africa. Vector Borne Zoonotic Dis. 10(7), 659-664 (2010).
30. Beasley DW, Li L, Suderman MT, Barrett AD: Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296(1), 17-23 (2002).
31. Bakonyi T, Hubalek Z, Rudolf I, Nowotny N: Novel flavivirus or new lineage of West Nile virus, central Europe. Emerg. Infect. Dis. 11(2), 225-231 (2005). (Pubitemid 40239238)
32. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA: West Nile virus isolates from India: evidence for a distinct genetic lineage. J. Gen. Virol. 88(Pt 3), 875-884 (2007). (Pubitemid 46359557)
33. Blackburn NK, Thompson DL, Jupp PG: Antigenic relationship of West Nile strains by titre ratios calculated from cross-neutralization test results. Epidemiol. Infect. 99(2), 551-557 (1987).
34. Li L, Barrett AD, Beasley DW: Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335(1), 99-105 (2005). (Pubitemid 40489055)
35. Allain JP, Stramer SL, Carneiro-Proietti AB et al.: Transfusion- transmitted infectious diseases. Biologicals 37(2), 71-77 (2009).
36. Hinckley AF, OLeary DR, Hayes EB: Transmission of West Nile virus through human breast milk seems to be rare. Pediatrics 119(3), E666-E671 (2007). (Pubitemid 46407541)
37. Centers for Disease Control and Prevention: Interim guidelines for the evaluation of infants born to mothers infected with West Nile virus during pregnancy. MMWR Morb. Mortal. Wkly Rep. 53(7), 154-157 (2004).
38. Laboratory-acquired West Nile virus infections - United States, 2002. MMWR Morb. Mortal. Wkly Rep. 51(50), 1133-1135 (2002).
39. Klee AL, Maidin B, Edwin B et al.: Long-term prognosis for clinical West Nile virus infection. Emerg. Infect. Dis. 10(8), 1405-1411 (2004). (Pubitemid 39014153)
40. Sadek JR, Pergam SA, Harrington JA et al.: Persistent neuropsychological impairment associated with West Nile virus infection. J. Clin. Exp. Neuropsychol. 1-8 (2009).
41. Sejvar JJ, Curns AT, Welburg L et al.: Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J. Neuropsychol. 2(Pt 2), 477-499 (2008).
42. Carson PJ, Konewko P, Wold KS et al.: Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin. Infect. Dis. 43(6), 723-730 (2006). (Pubitemid 44330735)
43. Murray K, Walker C, Herrington E et al.: Persistent infection with West Nile virus years after initial infection. J. Infect. Dis. 201(1), 2-4 (2010).
44. Georges AJ, Lesbordes JL, Georges-Courbot MC, Meunier DMY, Gonzalez JP: Fatal hepatitis from West Nile virus. Ann. Inst. Pasteur. Virol. 138, 237-244 (1987). (Pubitemid 17078707)
45. Paddock CD, Nicholson WL, Bhatnagar J et al.: Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin. Infect. Dis. 42(11), 1527-1535 (2006).
46. Markoff L: Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18(Suppl. 2), 26-32 (2000). (Pubitemid 30251999)
47. Amanna IJ, Messaoudi I, Slifka MK: Protective immunity following vaccination: how is it defined? Hum. Vaccin. 4(4), 316-319 (2008).
48. Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD: Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25(21), 4130-4139 (2007). (Pubitemid 46635942)
49. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC: The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375(6529), 291-298 (1995).
50. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH: Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80(23), 11467-11474 (2006). (Pubitemid 44788862)
51. Roehrig JT: Antigenic structure of flavivirus proteins. Adv. Virus Res. 59, 141-175 (2003). (Pubitemid 137640952)
52. Throsby M, Geuijen C, Goudsmit J et al.: Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J. Virol. 80(14), 6982-6992 (2006). (Pubitemid 44025197)
53. Oliphant T, Nybakken GE, Austin SK et al.: Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81(21), 11828-11839 (2007).
54. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM: Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392(1), 103-113 (2009).
55. Guy B, Barban V, Mantel N et al.: Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80(2), 302-311 (2009).
56. Schlesinger JJ, Brandriss MW, Walsh EE: Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 135(4), 2805-2809 (1985). (Pubitemid 16217156)
57. Engle MJ, Diamond MS: Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77(24), 12941-12949 (2003). (Pubitemid 37494289)
58. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD: Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. NY Acad. Sci. 951, 286-297 (2001). (Pubitemid 34060052)
59. Kimura-Kuroda J, Yasui K: Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141(10), 3606-3610 (1988).
60. Chung KM, Nybakken GE, Thompson BS et al.: Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc g receptor-dependent and -independent mechanisms. J. Virol. 80(3), 1340-1351 (2006). (Pubitemid 43134091)
61. Shiryaev SA, Radichev IA, Ratnikov BI et al.: Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus. Biochem. J. 427(3), 369-376 (2010).
62. Thomas S, Redfern JB, Lidbury BA, Mahalingam S: Antibody-dependent enhancement and vaccine development. Expert Rev. Vaccines 5(4), 409-412 (2006). (Pubitemid 44627873)
63. Pierson TC, Xu Q, Nelson S et al.: The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1(2), 135-145 (2007). (Pubitemid 46554914)
64. Halstead SB: Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421-467 (2003). (Pubitemid 137639381)
65. Broker M, Kollaritsch H: After a tick bite in a tick-borne encephalitis virus endemic area: current positions about postexposure treatment. Vaccine 26(7), 863-868 (2008).
66. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ: Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 104(22), 9422-9427 (2007). (Pubitemid 47185795)
67. Balsitis SJ, Williams KL, Lachica R et al.: Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6(2), E1000790 (2010).
68. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M: Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl. Infect. Dis. 4(3), 160-162 (2002). (Pubitemid 35364781)
69. Rager-Zisman B, Ben Nathan D: Efficacy of prophylactic and therapeutic human immunoglobulin on West Nile virus infection. Isr. Med. Assoc. J. 5(10), 691 (2003). (Pubitemid 37369030)
70. Shimoni Z, Niven MJ, Pitlick S, Bulvik S: Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg. Infect. Dis. 7(4), 759 (2001). (Pubitemid 32845276)
71. Planitzer CB, Modrof J, Kreil TR: West Nile virus neutralization by US plasma-derived immunoglobulin products. J. Infect. Dis. 196(3), 435-440 (2007). (Pubitemid 47093894)
72. Ben-Nathan D, Gershoni-Yahalom O, Samina I et al.: Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect. Dis. 9, 18 (2009).
73. Saquib R, Randall H, Chandrakantan A, Spak CW, Barri YM: West Nile virus encephalitis in a renal transplant recipient: the role of intravenous immunoglobulin. Am. J. Kidney Dis. 52(5), E19-E21 (2008).
74. Makhoul B, Braun E, Herskovitz M, Ramadan R, Hadad S, Norberto K: Hyperimmune g-globulin for the treatment of West Nile virus encephalitis. Isr. Med. Assoc. J. 11(3), 151-153 (2009).
75. Haley M, Retter AS, Fowler D, Gea-Banacloche J, OGrady NP: The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin. Infect. Dis. 37(6), e88-90 (2003).
76. Penn RG, Guarner J, Sejvar JJ et al.: Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin. Infect. Dis. 42(5), 680-683 (2006). (Pubitemid 43271383)
77. Levi ME, Quan D, Ho JT, Kleinschmidt-Demasters BK, Tyler KL, Grazia TJ: Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin. Transplant 24(2), 223-228 (2010).
78. Oliphant T, Engle M, Nybakken GE et al.: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11(5), 522-530 (2005). (Pubitemid 40685975)
79. Morrey JD, Siddharthan V, Olsen AL et al.: Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 194(9), 1300-1308 (2006). (Pubitemid 44630976)
80. Morrey JD, Siddharthan V, Olsen AL et al.: Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob. Agents Chemother. 51(7), 2396-2402 (2007). (Pubitemid 47047316)
81. Sultana H, Foellmer HG, Neelakanta G et al.: Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J. Immunol. 183(1), 650-660 (2009).
82. Vogt MR, Moesker B, Goudsmit J et al.: Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J. Virol. 83(13), 6494-6507 (2009).
83. Ledizet M, Kar K, Foellmer HG et al.: Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus. J. Infect. Dis. 196(12), 1741-1748 (2007). (Pubitemid 351411933)
84. Gould LH, Sui J, Foellmer H et al.: Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79(23), 14606-14613 (2005). (Pubitemid 41636259)
85. Beigel JH, Nordstrom JL, Pillemer SR et al.: Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob. Agents Chemother. 54(6), 2431-2436 (2010).
86. Lai H, Engle M, Fuchs A et al.: Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc. Natl Acad. Sci. USA 107(6), 2419-2424 (2010).
87. Pereboev A, Borisevich V, Tsuladze G et al.: Genetically delivered antibody protects against West Nile virus. Antiviral Res. 77(1), 6-13 (2008).
88. Beasley DW, Barrett AD: Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76(24), 13097-13100 (2002). (Pubitemid 35386997)
89. Zhang S, Vogt MR, Oliphant T et al.: Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J. Infect. Dis. 200(2), 202-205 (2009).
90. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ: Equine vaccine for West Nile virus. Dev. Biol. (Basel) 114, 221-227 (2003).
91. El Garch H, Minke JM, Rehder J et al.: A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet. Immunol. Immunopathol. 123(3-4), 230-239 (2008).
92. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J: Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3), 632-649 (2010).
93. Davis BS, Chang GJ, Cropp B et al.: West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75(9), 4040-4047 (2001). (Pubitemid 32410116)
94. Monath TP, Liu J, Kanesa-Thasan N et al.: A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA 103(17), 6694-6699 (2006).
95. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR: Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24(40-41), 6392-6404 (2006). (Pubitemid 44331996)
96. Martin JE, Pierson TC, Hubka S et al.: A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase I clinical trial. J. Infect. Dis. 196(12), 1732-1740 (2007). (Pubitemid 351411932)
97. Lieberman MM, Clements DE, Ogata S et al.: Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 25(3), 414-423 (2007). (Pubitemid 44856100)
98. Lieberman MM, Nerurkar VR, Luo H et al.: Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin. Vaccine Immunol. 16(9), 1332-1337 (2009).
99. Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV: Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am. J. Trop. Med. Hyg. 66(2), 115-116 (2002). (Pubitemid 34755639)
100. Tang F, Zhang JS, Liu W et al.: Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, Peoples Republic of China. Am. J. Trop. Med. Hyg. 78(6), 999-1001 (2008). (Pubitemid 351967822)
101. Yamshchikov G, Borisevich V, Kwok CW et al.: The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus. Vaccine 23(39), 4785-4792 (2005). (Pubitemid 41557329)
102. Nemeth NM, Bosco-Lauth AM, Bowen RA: Cross-protection between West Nile and Japanese encephalitis viruses in red-winged blackbirds (Agelaius phoeniceus). Avian Dis. 53(3), 421-425 (2009).
103. Ishikawa T, Widman DG, Bourne N, Konishi E, Mason PW: Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine 26(22), 2772-2781 (2008).
104. Fang Y, Reisen WK: Previous infection with West Nile or St. Louis encephalitis viruses provides cross protection during reinfection in house finches. Am. J. Trop. Med. Hyg. 75(3), 480-485 (2006). (Pubitemid 46941309)
105. Goverdhan MK, Kulkarni AB, Gupta AK, Tupe CD, Rodrigues JJ: Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol. 36(3), 277-283 (1992).
106. Malkinson M, Banet C, Khinich Y, Samina I, Pokamunski S, Weisman Y: Use of live and inactivated vaccines in the control of West Nile fever in domestic geese. Ann. NY Acad. Sci. 951, 255-261 (2001). (Pubitemid 34060049)
107. Takasaki T, Yabe S, Nerome R, Ito M, Yamada K, Kurane I: Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 21(31), 4514-4518 (2003). (Pubitemid 37315770)
108. Lim CK, Takasaki T, Kotaki A, Kurane I: Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 374(1), 60-70 (2008).
109. Gubler DJ: The continuing spread of West Nile virus in the western hemisphere. Clin. Infect. Dis. 45(8), 1039-1046 (2007). (Pubitemid 47580356)
110. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M: Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol. 83(6), 2436-2445 (2009).
111. Lobigs M, Pavy M, Hall R: Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21(15), 1572-1579 (2003). (Pubitemid 36287591)
112. Shrestha B, Diamond MS: Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 78(15), 8312-8321 (2004). (Pubitemid 38944315)
113. McMurtrey CP, Lelic A, Piazza P et al.: Epitope discovery in West Nile virus infection: identification and immune recognition of viral epitopes. Proc. Natl Acad. Sci. USA 105(8), 2981-2986 (2008). (Pubitemid 351723654)
114. Kim S, Li L, McMurtrey CP et al.: Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T-cell immunity against lethal West Nile virus infection. J. Immunol. 184(8), 4423-4430 (2010).
115. Seino KK, Long MT, Gibbs EP et al.: Comparative efficacies of three commercially available vaccines against West Nile virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin. Vaccine Immunol. 14(11), 1465-1471 (2007). (Pubitemid 350304041)
116. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS: The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26(16), 2020-2033 (2008).
117. Samina I, Khinich Y, Simanov M, Malkinson M: An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23(41), 4955-4958 (2005). (Pubitemid 41242873)
118. Samina I, Havenga M, Koudstaal W et al.: Safety and efficacy in geese of a PER. C6-based inactivated West Nile virus vaccine. Vaccine 25(49), 8338-8345 (2007). (Pubitemid 350087378)
119. Orlinger KK, Holzer GW, Schwaiger J et al.: An inactivated West Nile virus vaccine derived from a chemically synthesized cDNA system. Vaccine 28(19), 3318-3324 (2010).
120. Kinney RM, Huang CY, Whiteman MC et al.: Avian virulence and thermostable replication of the North American strain of West Nile virus. J. Gen. Virol. 87(Pt 12), 3611-3622 (2006). (Pubitemid 44816993)
121. Qiao M, Ashok M, Bernard KA et al.: Induction of sterilizing immunity against West Nile virus (WNV), by immunization with WNV-like particles produced in insect cells. J. Infect. Dis. 190(12), 2104-2108 (2004). (Pubitemid 39636357)
122. Siirin MT, Travassos da Rosa AP, Newman P et al.: Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. Am. J. Trop. Med. Hyg. 79(6), 955-962 (2008).
123. Watts DM, Tesh RB, Siirin M et al.: Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25(15), 2913-2918 (2007). (Pubitemid 46412562)
124. Fassbinder-Orth CA, Hofmeister EK, Weeks-Levy C, Karasov WH: Oral and parenteral immunization of chickens (Gallus gallus) against West Nile virus with recombinant envelope protein. Avian Dis. 53(4), 502-509 (2009).
125. Jarvi SI, Lieberman MM, Hofmeister E, Nerurkar VR, Wong T, Weeks-Levy C: Protective efficacy of a recombinant subunit West Nile virus vaccine in domestic geese (Anser anser). Vaccine 26(42), 5338-5344 (2008).
126. Ledizet M, Kar K, Foellmer HG et al.: A recombinant envelope protein vaccine against West Nile virus. Vaccine 23(30), 3915-3924 (2005). (Pubitemid 40726185)
127. Bonafe N, Rininger JA, Chubet RG et al.: A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 27(2), 213-222 (2009).
128. Demento SL, Eisenbarth SC, Foellmer HG et al.: Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27(23), 3013-3021 (2009).
129. Chu JH, Chiang CC, Ng ML: Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178(5), 2699-2705 (2007).
130. McDonald WF, Huleatt JW, Foellmer HG et al.: A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195(11), 1607-1617 (2007). (Pubitemid 46799218)
131. Gershoni-Yahalom O, Landes S, Kleiman-Shoval S et al.: Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge. Immunology (2010).
132. Choi KS, Nah JJ, Ko YJ, Kim YJ, Joo YS: The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization. Virus Res. 123(2), 216-218 (2007).
133. Mason PW, Shustov AV, Frolov I: Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351(2), 432-443 (2006). (Pubitemid 44108076)
134. Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, Mason PW: RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27(41), 5550-5553 (2009).
135. Widman DG, Ishikawa T, Giavedoni LD et al.: Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a nonhuman primate model of West Nile virus infection. Am. J. Trop. Med. Hyg. 82(6), 1160-1167 (2010).
136. Suzuki R, Fayzulin R, Frolov I, Mason PW: Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: use in safer propagation of a novel vaccine candidate. J. Virol. 82(14), 6942-6951 (2008). (Pubitemid 351977715)
137. Bunning ML, Fox PE, Bowen RA et al.: DNA vaccination of the American crow (Corvus brachyrhynchos) provides partial protection against lethal challenge with West Nile virus. Avian Dis. 51(2), 573-577 (2007). (Pubitemid 46878707)
138. Chang GJ, Davis BS, Stringfield C, Lutz C: Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection. Vaccine 25(12), 2325-2330 (2007). (Pubitemid 46237684)
139. Turell MJ, Bunning M, Ludwig GV et al.: DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus). Emerg. Infect. Dis. 9(9), 1077-1081 (2003). (Pubitemid 37071548)
140. Martin JE, Pierson TC, Graham BS: Reply to Rottinghaus and Poland. J. Infect. Dis. 197(11), 1628-1629 (2008). (Pubitemid 351706496)
141. Ishikawa T, Takasaki T, Kurane I, Nukuzuma S, Kondo T, Konishi E: Coimmunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect. 9(9), 1089-1095 (2007). (Pubitemid 47284941)
142. Ramanathan MP, Kutzler MA, Kuo YC et al.: Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 27(32), 4370-4380 (2009).
143. Bellier B, Huret C, Miyalou M et al.: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27(42), 5772-5780 (2009).
144. Seregin A, Nistler R, Borisevich V et al.: Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives. Virology 356(1-2), 115-125 (2006). (Pubitemid 44750041)
145. Hall RA, Nisbet DJ, Pham KB, Pyke AT, Smith GA, Khromykh AA: DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proc. Natl Acad. Sci. USA 100(18), 10460-10464 (2003). (Pubitemid 37071900)
146. Chang DC, Liu WJ, Anraku I et al.: Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat. Biotechnol. 26(5), 571-577 (2008). (Pubitemid 351668041)
147. Anwar A, Chandrasekaran A, Ng ML, Marques E, August JT: West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology 332(1), 66-77 (2005). (Pubitemid 40127230)
148. Dhalia R, Maciel M Jr, Cruz FS et al.: Membrane and envelope virus proteins coexpressed as lysosome associated membrane protein (LAMP) fused antigens: a potential tool to develop DNA vaccines against flaviviruses. An. Acad. Bras. Cienc. 81(4), 663-669 (2009).
149. Minke JM, Siger L, Karaca K et al.: Recombinant canarypox virus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. 18, 221-230 (2004).
150. Karaca K, Bowen R, Austgen LE et al.: Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 23(29), 3808-3813 (2005). (Pubitemid 40704744)
151. Rosas CT, Tischer BK, Perkins GA, Wagner B, Goodman LB, Osterrieder N: Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). Virus Res. 125(1), 69-78 (2007). (Pubitemid 46413390)
152. Iyer AV, Pahar B, Boudreaux MJ et al.: Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune
153. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F: Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191(2), 207-214 (2005). (Pubitemid 40096378)
154. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P: A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J. Gene Med. 8(3), 265-274 (2006).
155. Coutant F, Frenkiel MP, Despres P, Charneau P: Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3(12), E3973 (2008).
156. Schepp-Berglind J, Luo M, Wang D et al.: Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin. Vaccine Immunol. 14(9), 1117-1126 (2007). (Pubitemid 47518078)
157. Arroyo J, Miller C, Catalan J et al.: ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78(22), 12497-12507 (2004). (Pubitemid 39458768)
158. Long MT, Gibbs EP, Mellencamp MW et al.: Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live flavivirus chimera, in horses with a clinical disease challenge model. Equine Vet. J. 39(6), 491-497 (2007). (Pubitemid 351716098)
159. Langevin SA, Arroyo J, Monath TP, Komar N: Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus). Am. J. Trop. Med. Hyg. 69(1), 78-80 (2003).
160. Johnson BW, Chambers TV, Crabtree MB, Arroyo J, Monath TP, Miller BR: Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med. Vet. Entomol. 17(3), 235-243 (2003). (Pubitemid 37123924)
161. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM: Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314(1), 190-195 (2003). (Pubitemid 37153309)
162. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW: West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl Acad. Sci. USA 99(5), 3036-3041 (2002). (Pubitemid 34240581)
163. Hanley KA, Goddard LB, Gilmore LE et al.: Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors. Vector Borne Zoonotic Dis. 5(1), 1-10 (2005). (Pubitemid 41309107)
164. Huang CY, Silengo SJ, Whiteman MC, Kinney RM: Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J. Virol. 79(12), 7300-7310 (2005). (Pubitemid 40756765)
165. Yamshchikov G, Borisevich V, Seregin A et al.: An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330(1), 304-312 (2004). (Pubitemid 39446587)
166. Whiteman MC, Li L, Wicker JA et al.: Development and characterization of nonglycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 28(4), 1075-1083 (2010).
167. Yu L, Robert Putnak J, Pletnev AG, Markoff L: Attenuated West Nile viruses bearing 3SL and envelope gene substitution mutations. Vaccine 26(47), 5981-5988 (2008).
168. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA: A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit a/b interferon induction and attenuates virus virulence in mice. J. Virol. 80(5), 2396-2404 (2006). (Pubitemid 43271545)
169. Wicker JA, Whiteman MC, Beasley DW et al.: A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology 349(2), 245-253 (2006). (Pubitemid 43796242)
170. Terakawa N, Matsui Y, Satoi S et al.: Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr. Cancer 60(5), 643-651 (2008).
171. Wang S, Welte T, Fang H et al.: Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J. Nutr. 139(3), 598-602 (2009).
172. Yang X, Wang H, Beasley DW et al.: Selection of thioaptamers for diagnostics and therapeutics. Ann. NY Acad. Sci. 1082, 116-119 (2006). (Pubitemid 44955456)
173. Fennewald SM, Scott EP, Zhang L et al.: Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections. J. Gen. Virol. 88(Pt 3), 981-990 (2007). (Pubitemid 46359569)
174. Planitzer CB, Modrof J, Yu MY, Kreil TR: West Nile virus infection in plasma of blood and plasma donors, United States. Emerg. Infect. Dis. 15(10), 1668-1670 (2009).
175. Busch MP, Wright DJ, Custer B et al.: West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg. Infect. Dis. 12(3), 395-402 (2006).
176. Schellenberg TL, Anderson ME, Drebot MA et al.: Seroprevalence of West Nile virus in Saskatchewans Five Hills Health Region, 2003. Can. J. Public Health 97(5), 369-373 (2006). (Pubitemid 44614009)
177. Tonjes DJ: Estimates of worst case baseline West Nile virus disease effects in a suburban New York county. J. Vector Ecol. 33(2), 293-304 (2008).
178. Brault AC: Changing patterns of West Nile virus transmission: altered vector competence and host susceptibility. Vet. Res. 40(2), 43 (2009).
179. Davis CT, Beasley DW, Guzman H et al.: Emergence of attenuated West Nile virus variants in Texas, 2003. Virology 330(1), 342-350 (2004). (Pubitemid 39446591)
180. Beasley DW, Davis CT, Estrada-Franco J et al.: Genome sequence and attenuating mutations in West Nile virus isolate from Mexico. Emerg. Infect. Dis. 10(12), 2221-2224 (2004). (Pubitemid 39587353)
181. Ruiz MO, Chaves LF, Hamer GL et al.: Local impact of temperature and precipitation on West Nile virus infection in Culex species mosquitoes in northeast Illinois, USA. Parasit. Vectors 3(1), 19 (2010).
182. Wang G, Minnis RB, Belant JL, Wax CL: Dry weather induces outbreaks of human West Nile virus infections. BMC Infect. Dis. 10, 38 (2010).
183. Weinhold B: Rainy day reaction: human West Nile viruses cases respond to weather patterns. Environ. Health Perspect. 117(7), A311 (2009).
184. CDC West Nile virus homepage www.cdc.gov/westnile
185. US FDA: New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible www.fda.gov/OHRMS/DOCKETS/98fr/053102a.htm
186. NIH clinical trials database clinicaltrials.gov
187. PreveNile® recall letter www.prevenile.com/PDF/PreveNile%20Letter.pdf